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Abstract
Therapies that target cancer stem cells (CSCs) hold promise in eliminating cancer burden. 
However, normal stem cells are likely to be targeted due to their similarities to CSCs. It is 
established that EpCAM is a biomarker for normal hepatic stem cells and EpCAM+AFP+ 
hepatocellular carcinoma (HCC) cells have enriched hepatic CSCs. We sought to determine if 
specific miRNAs exist in hepatic CSCs that are not expressed in normal hepatic stem cells. We 
performed a pair-wised comparison of the miRNA transcriptome of EpCAM+ and corresponding 
EpCAM− cells isolated from two primary HCC specimens, as well as from two fetal livers and 
three healthy adult liver donors via small RNA deep sequencing. We found that miR-150, 
miR-155 and miR-223 were preferentially highly expressed in EpCAM+ HCC cells, which was 
further validated. Their gene surrogates, identified using miRNA and mRNA profiling in a cohort 
of 292 HCC patients, were associated with patient prognosis. We further demonstrated that 
miR-155 was highly expressed in EpCAM+ HCC cells compared to corresponding EpCAM− HCC 
cells, fetal livers with enriched normal hepatic progenitors, and normal adult livers with enriched 
mature hepatocytes. Suppressing miR-155 resulted in a decreased EpCAM+ fraction in HCC cells 
and reduced HCC cell colony formation, migration and invasion in vitro. The reduced levels of 
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identified miR-155 targets predicted the shortened overall survival and time to recurrence of HCC 
patients. Conclusion: MiR-155 was highly elevated in EpCAM+ HCC cells and might serve as a 
molecular target to eradicate the EpCAM+ CSC population in human HCCs.
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Introduction
Cancer stem cells (CSCs) are defined by their abilities to give rise to a new tumor 
possessing all cell types in the original cancer. They are thought to be responsible for cancer 
metastasis and tumor relapse (1, 2). Eradicating CSCs may be a critical step to achieve 
stable tumor remission, or even a cure, of aggressive malignances. However, CSCs and 
normal stem cells share many common cellular properties (e.g., self-renewal, differentiation) 
and molecular signaling pathways (e.g., Wnt/β-catenin, TGF-beta, Notch) (1, 3–11), which 
precludes the development of therapeutics that can specifically target CSCs. Therefore, one 
of the major hurdles in CSC eradiation is our poor understanding of molecular changes 
specific to CSCs but not to normal stem/progenitor cells.
Hepatocellular carcinoma (HCC), a major type of primary liver cancer, is the second most 
common cause of cancer-related mortality worldwide in men (12, 13)(Globocan2012). 
Studies have indicated that epithelial cell adhesion molecule (EpCAM) is a normal human 
hepatic stem cell (HpSC) marker, and that EpCAM+ cells isolated from AFP+ HCC clinical 
specimens or cell lines are hepatic CSCs (4, 5, 14, 15). Several technologies including 
transcriptomic and metabolomic profiling have been used to characterize HCC specimens 
with high level of EpCAM and AFP (EpCAM+AFP+ HCC) (3, 5, 16–18). However, 
molecular features associated with EpCAM+AFP+ HCCs are commonly found in EpCAM+ 
normal HpSCs, such as the activation of Wnt/beta-catenin pathway and the up-regulation of 
microRNA-181s (1, 3, 19). Little is known about the global molecular alterations specific to 
hepatic CSCs. To search for CSC-specific molecular traits, one strategy is to perform a pair 
wise comparison of molecular profiles between EpCAM+ HCC cells and EpCAM− HCC 
cells isolated from the same AFP+ HCC patients and then to normal EpCAM+ hepatic stem/
progenitor cells.
MicroRNAs (miRNAs) are a class of ~22-nt non-coding RNA molecules that repress gene 
expression at the post-transcriptional level under normal and pathological conditions. They 
are functionally linked to normal stem cells and CSCs, are relevant to cancer therapy, and 
are expressed in a tissue/cell-specific manner (20–24). High-throughput next-generation 
sequencing has become the technology of choice for analyzing miRNA expression with an 
increased sensitivity and accuracy. This technology is able to detect a full-length miRNA 
within a single read, and can distinguish miRNAs that are very similar in sequence, thereby 
producing a precise count of each type of miRNA (25, 26). Thus, this technology, in 
principle, may provide sufficient resolutions to detect molecular changes specific to hepatic 
CSCs.
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In this vein, we used a small RNA deep sequencing approach to profile the miRNA 
transcriptome of EpCAM+ cells and corresponding EpCAM− cells from primary HCC 
clinical specimens, HCC cell lines, as well as normal livers. We identified several miRNAs 
including miR-150, miR-155, miR-223 that were specific to EpCAM+ HCC cells. We 
further demonstrated that miR-155 was highly elevated in EpCAM+ HCC cells compared to 
the rest groups of cells, and that blockage of miR-155 resulted in a decreased EpCAM+ 
HCC cell proportion and the reduced HCC spheroid formation, colony formation, cellular 
migration and invasion.
Materials and Methods
Cell sorting from fresh HCC samples and HCC cells, HpSC and HB cell isolation, primary 
human hepatocytes isolation, hESC cell culture
Cell sorting from fresh HCC samples and cell lines was done as we did previously (3, 5, 16). 
Cell sorting for EpCAM+ cells from primary HCC tumor was done using magnetic-activated 
cell sorting (MACS) according to manufacturer’s instructions (Miltenyi Biotec, Auburn, 
CA). EpCAM microBeads (Miltenyi Biotec, CA) were used. EpCAM− cells were mainly 
HCC cells after depletion of EpCAM+ HCC cells. The purity of sorted cells was evaluated 
by FACS. The research protocol was reviewed and approved by the local Institutional 
Review Board. Cell sorting for EpCAM+ cells from cultured HCC cells were done via a BD 
FACSAria cell sorting system (BD Biosciences). FITC-conjugated anti-EpCAM monoclonal 
antibody Clone Ber-EP4 (DAKO, Carpinteria, CA) was used.
Human HpSCs and HBs were isolated from fetal livers and primary human hepatocytes 
were isolated from healthy adult liver donors using protocols published previously (15, 27, 
28). Detailed information was in Supplementary Supporting text. Human ESCs, H9 and H1 
cells (WiCell Institute, Madison, WI, USA) were cultured as described in the standard 
protocols http://www.wicell.org. The inactivated MEF cells (Applied StemCell Inc, CA, 
USA) were used as the feeder layer. Cells were incubated at 37°C in 5% of CO2 in air.
Other Materials and Methodologies are described in detail in the Supplementary Supporting 
text.
Results
Small RNA deep sequencing of EpCAM+ and EpCAM− cells from HCC and normal livers
To globally identify miRNA(s) specifically altered in hepatic CSCs but not in normal 
hepatic stem cells nor in differentiated HCC cells, we performed small RNA deep 
sequencing using the samples listed in Table 1. 1) EpCAM+ HCC cells and corresponding 
EpCAM− HCC cells isolated from two human primary AFP+ HCC specimens and two HCC 
cell lines; 2) normal HpSCs and their descendants, hepatoblasts (HB) isolated from two 
human fetal livers (14, 15); 3) primary hepatocytes isolated from three healthy liver donors. 
In addition, we included pooled H1 and H9 cell lines as human embryonic stem cell (hESC) 
positive controls to monitor the validity of our small RNA deep sequencing and downstream 
bioinformatics pipelines procedure since sequencing data and miRNA expression data are 
available for hESCs (29, 30). To monitor the validity of isolated primary EpCAM+ and 
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EpCAM− HCC cells, a group of stem cell-related genes and mature hepatocytes-related 
genes were examined. Supplementary Fig 1 showed that, in primary EpCAM+ HCC cells, 
four pluripotent stem cell markers (Lin28B, SOX2, NANOG, POU5F1) and two endodermal 
stem cells markers (PDX1, LGR5) expressed at higher levels, while mature hepatocyte-
related genes (CYP3A4 and GSTA1) expressed at lower levels compared to those in 
EpCAM− cells.
Sequencing analysis resulted in a total of 290.9 million reads. We found that 92.5 million 
reads (about 1/3) were aligned to human miRBase with the rest of 71.7 million reads to the 
human genome (Fig 1A, Supplementary Table 1). For the reads aligned to human miRBase, 
their size distribution was enriched in 21–24nt (Fig 1B), which was consistent with the size 
of mature miRNAs. In contrast, the size for reads aligned to human genome was about 
evenly distributed. Using our in-house bioinformatics analysis pipeline (Supplementary Fig 
2), we identified a total of 1231 known mature miRNAs, accounting for a total of 67.9 
million reads (Fig 1C, Supplementary Table 1). We have also identified 175 potential novel 
mature miRNAs from the mapped reads. However, for these miRNAs, the abundance was 
relative low (Supplementary Table 1) and only a few of them with the median read number 
was over 100 reads among 16 samples. Therefore, only identified known miRNAs with a 
median of reads higher than three, 600 miRNAs, were used for further analysis. The total 
reads of 600 miRNAs counted for 99.9% of total reads (67.88 vs. 67.93 million reads).
Among these miRNAs, members of the miR-302 family were the most abundant miRNAs in 
hESCs, accounted for more than 21.4% of total reads (1.3 million/6.0 million) 
(Supplementary Fig 3A), while miR-122 was the most abundant miRNA in differentiated 
hepatocytes, accounted for more than 24.4% of total reads (0.6 million/ 2.4 million) 
(Supplementary Fig 3B). These results were consistent with the reported data (29–32), 
confirming the validity of our small RNA sequencing and the downstream bioinformatics 
pipelines.
Comparison of whole miRNA transcriptome between EpCAM+ and EpCAM− cells from HCC 
and normal livers
To compare the difference of the miRNA transcriptome among EpCAM+ and EpCAM− 
cells from HCC and normal livers, we first normalized the expression data of 600 miRNAs 
based on the total mapped reads in each corresponding samples (Supplementary Fig 4) and 
then performed an unsupervised hierarchical clustering. Unsupervised clustering analysis 
revealed 2 distinct groups. One contained cultured HCC cell lines while the other contained 
primary cells (Fig 2A). Because cultured HCC cell lines have very distinct small RNA 
transcriptome profiles compared to those of primary cells, we only included data from 
primary cells for the initial data analysis.
We found that 99 out of 600 miRNAs were differentially expressed between EpCAM+ and 
EpCAM− HCC cells from two primary HCC cases with an average fold change of more than 
2. Meanwhile, 301 of 600 miRNAs were differentially expressed between HpSC (and HB) 
and hepatocytes (≥2 folds). Among them, 22 miRNAs had the consistent alteration from the 
comparison of EpCAM+ and EpCAM− cells (21 up and 1 down) in both tumor and normal 
cells (Fig 2B, left panel). MiR-181c was one of 21 up-regulated miRNAs in both EpCAM+ 
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HCC cells and normal hepatic progenitors (Supplementary Fig 5), which was consistent with 
our previous findings (3, 19).
Identification of miRNAs specific to EpCAM+ HCC cells
We utilized a stringent criterion to further define miRNAs specific to EpCAM+ HCC cells 
due to the limited sample size for sequencing. We first identified 28 miRNAs with > 5-folds 
between EpCAM+ and EpCAM− HCC cells (Fig 2B, right panel; 21 upregulated and 7 
downregulated miRNAs in EpCAM+ HCC cells). Our candidate miRNAs were then 
restricted to those with less than 2-fold changes in normal liver cell comparison. As shown 
in Fig 2C, we identified 10 miRNAs as candidates specific to EpCAM+ HCC cells.
We performed qRT-PCR to validate the sequencing results. Seven miRNAs were included 
because of the availability of probes for qRT-PCR. As shown in Fig 2D, there was a 
significant correlation between the qRT-PCR data and sequencing data.
EpCAM+AFP+ HCC cases had metastatic feature and short survival, and activated CSC 
gene signaling signatures, while EpCAM−AFP− HCC cases had good prognosis and 
activated mature hepatocyte gene signatures (3, 5, 33). We therefore examined if a 
differential expression of candidate miRNAs can be found among EpCAM+AFP+ and 
EpCAM−AFP− tumor samples. We examined HCC cases with available miRNA expression 
data (GSE6857; Cohort 1) (3, 34, 35), especially those with extreme expression spectrums 
on EpCAM and AFP. Among ten candidate miRNAs (listed in Fig 2C), three miRNAs 
(miR-150, miR-155, and miR-223) were included in this miRNA array dataset. Consistently, 
all three miRNAs were significantly elevated in extreme EpCAM+AFP+ HCCs compared to 
extreme EpCAM−AFP− HCC cases (Fig 2E).
We further searched mRNAs as functional surrogates that were significantly correlated with 
miR-150, miR-155, and miR-223. In cohort 1, 196 HCC samples had both miRNA and 
mRNA expression data (GSE14520) (34, 36) (Fig 3A). We found that 511 genes were 
significantly correlated with all three miRNAs (Fig 3B). Hierarchical clustering of these 511 
genes revealed that they can significantly discriminate EpCAM+AFP+ cases from 
EpCAM−AFP− HCC cases (Fig 3C). Furthermore, these gene surrogates could predict 
overall survival and time to recurrence (Fig 3D). These results were validated in another 
independent HCC cohort with 139 HCC cases (GSE1898 and GSE4024; Cohort 2)(37, 38) 
(Fig 3E). Cytokeratin 19 (CK19) has been reported as a predictive marker for poor prognosis 
of HCC patients and related to hepatic CSCs (39, 40). We thus compared the expression of 
CK19 in the two clusters predicted by gene surrogates of EpCAM+ HCC cells-related 
miRNAs. Using the available mRNA microarray data in two HCC cohorts, we found that 
CK19 expression level was significantly higher in cluster 2 patients with poor prognosis 
compared to that in cluster 1 patients with good prognosis in both cohorts (p<0.001, 
Supplementary Fig 6). Thus, gene surrogates of EpCAM+ HCC cells-related miRNAs were 
associated with metastatic features and patient prognosis.
MiR-155 overexpression in EpCAM+ HCC cells
MiR-155 was chosen for further analysis because of its high abundance in EpCAM+ primary 
HCC cells compared to EpCAM− HCC cells, normal hepatic progenitor cells and 
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hepatocytes (Fig 4A; ≥5-fold). Since basal levels of miR-155 was very low in cultured 
HuH7 and HuH1 cells from either sequencing and qRT-PCR analyses, we first enriched 
EpCAM+ and EpCAM− HCC cells (Fig 4B, top panel) using the KnockOut medium/Serum 
Replacement culture and EpCAM siRNA methodologies described previously (3, 5, 33). 
Under these conditions, miR-155 was more abundantly expressed in EpCAM+ cells than in 
EpCAM− cells from HuH7 HCC cells (Fig 4B, bottom panel). We also found that hypoxia 
could enrich EpCAM+ CSC populations as previous reports (8, 41) and induced miR-155 
expression (Fig 4C-HuH7, Supplementary Fig 7-HuH1).
In contrast, miR-155 level in human adult livers and fetal livers was lower than that in 
enriched EpCAM+ HCC cells obtained from KnockOut medium culture methods (Fig 4D). 
We also examined miR-155 levels in different stages of mouse fetal livers and found the 
miR-155 level was low, with no change during mouse embryonic liver development (Fig. 
4E). As a control, miR-181d showed a gradual decline in its expression following the liver 
development from 11.5 to 15.5 days (fetal liver) and from 1 week to 15 weeks after birth 
(Fig. 4E). Collectively, we concluded that miR-155 was specifically highly expressed in 
EpCAM+ HCC cells, but not in EpCAM− HCC cells, nor in normal livers including fetal 
livers with more hepatic progenitors and adult livers with more differentiated hepatocytes.
HCC cells with suppressed miR-155 had reduced malignancy features
We hypothesized that silencing miR-155 could suppress HCC malignant features. 
MiRZip-155, a lentivirus vector encoding an anti-miR155 cassette, was used to suppress 
miR-155 functions via blocking the binding of miR-155 to its target genes. We found that 
cells with transfection of miRZip-155 had a reduced miR-155 activity determined by a 
luciferase reporter containing a miR-155 sequence at the 3’UTR (Fig 5A). We then 
examined whether MiRZip-155 can inhibit the malignant features of HCC cells. FACS 
analysis revealed that suppressing miR-155 by miRZip-155 led to a reduced EpCAM+ cell 
population in both HuH7 and HuH1 cells (Fig 5B, HuH7; Supplementary Fig 8A, HuH1). 
We have previously found that about 1–2% of HuH7 or HuH1 cells could form spheroids, a 
cell self-renewal feature (3, 5). Consistently, miRZip-155 was able to inhibit spheroid 
formation of HCC cells (Fig 5C, HuH7; Supplementary Fig 8B, HuH1). In addition, 
miRZip-155 was able to suppress colony formation, cell migration and invasion in HCC 
cells (Fig 5D, HuH7; Supplementary Fig 8C–E, HuH1). All these findings demonstrated that 
HCC cells with suppressed miR-155 had reduced HCC malignant features.
Since miR-155 may have multiple cellular targets, we searched its potential targets that are 
associated with the EpCAM+AFP+ HCC subtype using TargetScan and MiRDB. This 
analysis revealed a total of 789 predicted targets. Class comparisons revealed that 780 genes 
were significantly down-regulated in EpCAM+AFP+ HCC subtype compared to 
EpCAM−AFP− HCC subtype. Venn-diagram analysis revealed 27 overlapping genes 
between predicted targets and differentially expressed genes (Fig 6A, Supplementary Table 
2). Among them, CEBPB, SMAD1 and MYLK have been reported as miR-155 targets (42–
44). We determined if miR-155 can regulate CEBPB in HCC cells due to the abundant level 
of CEBPB, and found that miRZip-155 could induce CEBPB expression in HuH7 and HuH1 
cells (Fig 6B). To further determine if miR-155 may be functionally linked to the features of 
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EpCAM+AFP+ HCC subtype, we performed hierarchical clustering of 27 genes. We found 
that these genes could separate HCC into two main subgroups (Cohort 1) with one group 
having an overall low level of these 27 genes (Fig 6C). Furthermore, HCC cases with lower 
levels of these genes had a worse overall survival and a shortened time to recurrence (Fig 
6D). In addition, the association between low levels of these genes with poor HCC 
prognosis has been further validated in Cohort 2 (Fig 6E–F). As a control, the randomly 
selected 27 genes from 780 genes with down-regulation in EpCAM+AFP+ HCC had no 
significant association with either overall survival or time to recurrence in HCC cases 
(Supplementary Fig 9). Taken together, these results suggested that the identified 27 
potential miR-155 targets were likely a part of a miR-155 signaling pathway that was 
fundamentally associated with malignant features of hepatic CSCs.
Discussion
Cancer stem cells have been identified in many tumor types, including HCC, the fifth most 
common and second most deadly malignancy with observable heterogeneity (1). Numerous 
studies have shown that hepatic CSCs could be enriched via different cell surface markers 
including EpCAM (1, 5). Functional characterizations of hepatic CSCs have revealed 
several deregulated signaling pathways, such as Wnt/beta-catenin, AKT, TGF-beta 
pathways to be critical at inducing “stemness” of HCCs and in promoting self-renewal. 
Noticeably, these signaling pathways were also important in normal hepatic stem cells. 
Following the identification and characterization of hepatic CSCs, more and more studies 
have demonstrated that hepatic CSCs are responsible for metastasis and recurrence after 
HCC resection due to their ability to give rise to a new tumor at a local or distant site. The 
development of strategies specifically targeting hepatic CSCs may provide new methods that 
could be used to improve HCC patients’ survival. However, since the similarity of cancer 
and normal stem cells, one of the most therapeutically important challenges is a selective 
targeting and eradication of CSCs without sacrificing normal stem cells. There is a central 
need to understand the biological difference of hepatic CSCs and normal stem cells. The 
unique changes in hepatic CSCs compared to HCC cells with differentiated hepatocyte 
features as well as to normal hepatic stem cells and hepatocytes hold the hope as the potent 
therapeutic target to specifically eliminate hepatic CSCs.
We have previously found that EpCAM is a biomarker for both normal hepatic stem cells 
and hepatic CSCs. Here, we focus on the difference between EpCAM+ hepatic CSCs and 
EpCAM+ normal hepatic stem cells. Small RNA next-generation sequencing was used to 
globally and unbiasedly detect and quantify miRNAs. Our study compared the stemness-
related miRNAs in EpCAM+ HCC cells vs. EpCAM+ hepatic normal stem cells. We have 
found the difference of cancer and normal hepatic stem cells according to their miRNA 
expression profiling, and that a small group of miRNAs were remarkably altered in 
EpCAM+ HCC cells compared to EpCAM− HCC cells, but not in normal stem cells 
compared to hepatocytes. EpCAM− HCC cells have been showed to have less malignancy 
features but mature hepatocyte features (3, 5). Meanwhile, the gene surrogates of these 
EpCAM+ HCC cells specific miRNAs were significantly associated with clinical outcome of 
HCC patients. The presence of these miRNAs suggests the biological distinctions between 
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CSCs and normal stem cells, and the possibility of specifically targeting hepatic CSCs 
without sacrificing hepatic normal stem cells.
In the current study, we found that miR-155 is a miRNA highly related to EpCAM+ hepatic 
CSCs. It was highly expressed in EpCAM+ HCC cells compared to EpCAM− HCC cells, 
normal hepatic stem cells, hepatocytes, as well as normal fetal and adult livers. Functionally, 
silencing miR-155 resulted in altered EpCAM+ cell populations, and a reduced spheroid 
formation, colony formation, migration and invasion. The predicted miR-155 target genes, 
that were associated with EpCAM+AFP+ HCC subtype, could predict HCC survival in two 
independent cohorts. Thus miR-155 may be a novel molecular target for a stem-like HCC 
subtype. Further investigations should allow us to develop novel therapies to specifically 
eliminate hepatic CSCs without sacrificing normal stem cells to avoid unwanted side effect. 
Interestingly, miR-155 has been reported due to its potential role as a therapeutic target in B-
cell lymphoma (45).
The strength of our study is that we have used a sensitive small RNA deep sequencing 
method to identify miRNAs specific to hepatic CSCs. Our study design included the use of 
freshly isolated primary HCC cells to avoid potential artifacts derived from cultured cell 
lines. The limitation has been that we were able to analyze only two HCC donors due to the 
difficulties in obtaining fresh primary HCC tumor specimens for cell sorting of live 
EpCAM+ and EpCAM− cells. To allow our data being more representative, we have used 
the stringent criteria to screen the most significant candidate miRNAs (Fig 2B–C). To 
compensate and to strengthen our findings, we have utilized the available miRNA 
microarray data from a large cohort of HCC specimens to validate our results, and have used 
two HCC cohorts with a total of 335 HCC cases to examine whether the functional gene 
surrogates of these candidate miRNAs were associated the stem cell-related features. To 
further address the concern on the representation of our results from only two sequenced 
HCC samples, we have also investigated the function of miR-150 (another candidate 
miRNA) in regulating HCC malignancies. As shown in Supplementary Fig 10, suppressing 
miR-150 consistently led to a reduced EpCAM+ proportion in both HuH1 and HuH7 cells, 
and a decreased spheroid formation, colony formation and cell migration. However, the two 
sequenced samples and most of samples in two HCC cohorts were hepatitis B or C virus-
related patients. It remains unknown whether our data are also significant in other etiology-
related HCCs, such as alcoholic and nonalcoholic steatohepatitis -related HCC. In addition, 
many biomarkers besides EpCAM have been used to isolate the enriched hepatic CSC 
population and it remains unknown of the hierarchical relationship of these CSCs (1). We 
are planning to perform more work to test the association of miR-155 with these different 
hepatic CSCs from patients with various etiologies, as well as explore whether miR-155 can 
serve as an effective therapeutic target in eliminating CSCs in HCC.
In summary, we globally compared the miRNA transcriptome between EpCAM+ and 
EpCAM− cells from HCC specimens and normal livers by a small-RNA deep sequencing 
technology. We found that a small group of miRNAs were uniquely altered in EpCAM+ 
HCC cells. In addition, we validated the specific high level of miR-155 in EpCAM+ HCC 
cells, and found that targeting miR-155 could significantly suppress malignant features of 
HCC cells. Our results indicate that miR-155 may serve as an effective therapeutic target to 
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specifically eliminate EpCAM+ CSCs thereby preventing metastasis and tumor relapse in 
HCC patients.
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Figure 1. The raw sequencing data of small RNA transcriptome in 16 samples
(A) Histogram of all the reads from each output file of 16 sequenced samples. FL refers to 
fetal liver. (B). Read length distribution of reads aligned to miRBase (Black) and reads 
aligned to Genome (Orange) in 16 sequenced samples. The results are shown as mean ± 
standard deviation (SD). (C) The total number of identified miRNAs (grey bars) and the 
total raw reads number for identified miRNAs (Black dots) in each sample. An in-house 
pipeline was used to process the aligned reads. Details are shown in Materials and Methods.
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Figure 2. Aberrant high expression of three miRNAs in EpCAM+ HCC cells
(A) Unsupervised clustering of 16 sequenced samples based on the expression of 600 
miRNAs with relative high abundance. (B) Venn-diagram of miRNAs with ≥ 2-fold 
alteration in the comparison of EpCAM+ and EpCAM− HCC cells and miRNAs from the 
comparison of EpCAM+ and EpCAM− normal liver cells. The right panel shows the bar 
graph of 99 miRNAs with ≥ 2-fold changes in the comparison of EpCAM+ and EpCAM− 
HCC cells. Red bars: n=21, ≥5-fold of EpCAM+ HCC cells vs. EpCAM+ HCC cells. Blue 
bars: n=7, ≤0.2-fold of EpCAM+ HCC cells vs. EpCAM− HCC cells. (C) Scatter plot of 21 
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miRNAs (left channel, red spots) and 7 miRNAs (right channel, blue spots) from the right 
panel of Fig 2B to display their expression in EpCAM+ hepatic stem cells and hepatoblasts 
compared to EpCAM− hepatocytes. The red spots shadowed in red refer to miRNAs with ≥ 
5-fold of EpCAM+ HCC cells vs. EpCAM− HCC cells and ≤ 2-fold of EpCAM+ hepatic 
progenitors vs. EpCAM− hepatocytes. The blue spots shadowed in blue refer to miRNAs 
with ≤ 0.2-fold of EpCAM+ HCC cells vs. EpCAM− HCC cells and ≥ 0.5-fold of EpCAM+ 
hepatic progenitors vs. EpCAM− hepatocytes. (D) Pearson correlation analysis of EpCAM+ 
HCC cells-related miRNAs expression data (log2) from small RNA sequencing and from 
qRT-PCR validation in all 16 samples. The EpCAM+ HCC cells - related miRNAs were 
listed in (C). (E) miRNA array data for three miRNAs in extreme EpCAM+AFP+-HCCs and 
EpCAM−AFP−-HCCs. Y-axis refers to the log2 intensity. Student t-test was performed.
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Figure 3. Gene surrogates of EpCAM+ HCC cells-related miRNAs were associated with HCC 
prognosis
(A) We have used two HCC cohorts, i.e., HCC cohort 1 (n= 292) and HCC cohort 2 
(n=139). In cohort 1, 196 HCC cases had the available miRNA and mRNA array data, while 
45 patients have miRNA array data only and 51 patients have mRNA array data only. All 
patients in HCC cohort 2 have mRNA array data only. (B) Pearson correlation was 
performed between three EpCAM+ HCC cells-miRNAs and ~13,000 genes in 196 HCC 
cases with available miRNA and mRNA array from cohort 1. 511 gene surrogates of 
EpCAM+ HCC cells-related miRNAs were identified with the criteria described in Materials 
and Methods. (C) Unsupervised hierarchical clustering based on these gene surrogates for 
extreme EpCAM+AFP+ and EpCAM−AFP−HCCs with both miRNA and mRNA expression 
data (n=57). (D) Kaplan-Meier analysis of overall survival and recurrence in HCC cases 
from Cohort 1 (n=196, cases used for detecting gene surrogates) based on the classification 
of cluster 1 and cluster 2 by 511 genes. (E) Kaplan-Meier analysis of overall survival and 
recurrence in HCC cases from cohort 2 (n=139) based on the classification of cluster 1 and 
cluster 2 by 511 genes. Log-rank test was performed.
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Figure 4. miR-155 was specifically highly expressed in EpCAM+ HCC cells
(A) The sequencing data of miR-155 in EpCAM+ and EpCAM− cells from HCC primary 
samples and normal livers. (B) qRT-PCR data of miR-155 in enriched EpCAM+ and 
EpCAM− cells from HuH7 HCC cell line. EpCAM+ cells were enriched via KnockOut 
medium/Serum Replacement culture and cells under regular media were used as control. 
EpCAM− cells were enriched via EpCAM silencing technology and control siRNA was used 
as controls. MiR-155 expression in these cells was compared to the corresponding controls. 
The top channel is the FACS data showing the enriched EpCAM+ and EpCAM− population. 
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APC-conjugated EpCAM antibody was used. (C) EpCAM+ cell distribution (upper channel, 
FACS) and miR-155 expression (lower channel, qRT-PCR) in HuH7 cells under normoxia 
and hypoxia condition for two days. For FACS analysis, APC-conjugated EpCAM antibody 
was used. (D) qRT-PCR data of miR-155 in human fetal livers and normal livers. EpCAM+ 
HCC cells enriched from KnockOut medium/Serun Replacement culture were used as a 
control. (E) miR-155 expression during the development of mouse liver from embryonic 
stage to adult stage. MiR-181d was also examined as a positive control. (B,C,D) Student t-
test was performed.
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Figure 5. Suppressing miR-155 reduced HCC malignancy features in vitro
(A) The duplex between anti-miR-155 expressed from miRZip-155 and miR-155, and the 
reporter plasmid for miRZip-155 with mature miR-155 in the 3’UTR region of luciferase 
(left channel). The lower cases in mature miR-155 were mutated to ATCCCC in reporter 
plasmid with mutant miR-155. Luciferase activities of reporter plasmids with wild type and 
mutant miR-155 in 3’UTR region was measured in HuH7 cells co-transfected with 
miRZip-000 or miRZip-155 (right channel). The luciferase activity was shown as the mean 
± SD. (B) FACS analysis of HuH7 infected with miRZip-155 and control virus for 2 days 
under hypoxia condition. APC-conjugated EpCAM antibody was used. (C) HuH7 cells 
infected with miRZip-155 and control virus for 2 days under hypoxia condition were seeded 
in ultra-low attachment plates to assay spheroid formation. (D) Assays on colony formation, 
migration and invasion were performed in HuH7 infected with miRZip-155 and control 
virus for 2 days under hypoxia condition. (A,C,D) Student t-test was performed.
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Figure 6. The reduced level of miR-155 potential targets was associated with poor overall 
survival and short time to recurrence in HCC patients
(A) Venn-diagram of down-regulated genes in extreme EpCAM+ HCC cases and predicted 
miR-155 targets. 27 genes were overlapped, in which three genes were reported as miR-155 
targets. (B) The expression levels of CEBPB and Actin in HuH7 and HuH1 cells infected 
with miRZip-155, as determined by Western blotting. (C) Hierarchical clustering of 27 
genes in cohort 1 (n=247) predicted two HCC subgroups, i.e., group 1 (n=121) and group 2 
(n=126). The reduction of these genes was noticed in group 2. (D) Kaplan-Meier analysis of 
overall survival and recurrence in HCC cases from cohort 1 based on the classification of 
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group 1 and group 2 by 27 genes. (E) Hierarchical clustering of 27 genes in cohort 2 
(n=139) could predict two HCC subgroups, i.e., group 1 (n=73) and group 2 (n=66). The 
reduction of these genes was noticed in group 2. (F) Kaplan-Meier analysis of overall 
survival and recurrence in HCC cases from cohort 2 (n=139) based on the classification of 
group 1 and group 2 by 27 genes. Log-rank test was performed.
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